A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

计划入组 241 人 · 首次发布于 2025 年 10 月 9 日

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

计划入组 56 人 · 首次发布于 2024 年 10 月 15 日

The Safety and Dosimetry Study of 177Lu-LNC1004 Injection

计划入组 11 人 · 首次发布于 2023 年 2 月 13 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

BioLine Rx

Israel

Avacta's AVA6000 Shows Durable Responses in FAP-Positive Solid Tumors with Reduced Toxicity

Perspective Therapeutics, Merck Partner to Test [212Pb]PSV359 Plus Keytruda in FAP-α-Positive Solid Tumors

First Patient Dosed with PSV359 in Perspective Therapeutics' Phase 1/2a Trial for FAP-α Positive Solid Tumors